|
| 唑来膦酸对新疆维吾尔族老年男性骨质疏松患者的疗效观察 |
| Efficacy observation of zoledronic acid on osteoporosis in Uygur elderly male patients in Xinjiang |
| |
| DOI：10.3969/j.issn.1006-7108.2013.10.019 |
| 中文关键词: 唑来膦酸 骨质疏松 老年男性 维吾尔族 骨密度 |
| 英文关键词:Zoledronic acid Osteoporosis Elderly male Uygur BMD |
| 基金项目:民政部“十一.五”课题的子课题(民人教科字(2007)18-1-39) |
|
| 摘要点击次数: 1381 |
| 全文下载次数: 1729 |
| 中文摘要: |
| 目的 探讨注射用唑来膦酸5mg对新疆维吾尔族老年男性骨质疏松患者的临床疗效。方法 选取2010年6月至2011年11月住院期间维吾尔族老年男性骨质疏松患者43例，所有患者均初次诊断为骨质疏松症，未曾行任何抗骨质疏松治疗，同时排除其他骨代谢性疾病或药物影响，随机分为治疗组（22例，平均年龄73.2岁），给予唑来膦酸5mg,静脉滴注30min,同时口服钙尔奇600mg/d及阿尔法D3 0.25μg/d；对照组（21例，平均年龄73.8岁），给予口服钙尔奇600mg/d及阿尔法D3 0.25μg/d，治疗时间1年，采用双能X线骨密度仪(DXA)测定两组治疗前后的腰椎1-4、股骨颈、Wards三角区骨密度值。结果 排除治疗组中2例患者脱失外，治疗组骨密度增幅程度均显著高于对照组（P＜0.05）。5例患者在注射唑来膦酸后出现发热、头痛及流感样症状，给予NSAIDs对症治疗后5例患者均在3d内缓解，未见其他不良反应。结论 唑来膦酸注射液5mg可明显提高新疆维吾尔族老年男性骨质疏松患者的骨密度，抑制骨量丢失，降低骨折风险，提高患者依从性，不良反应可耐受，是治疗新疆维吾尔族老年男性骨质疏松患者的新一类高效药物。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy of 5mg zoledronic acid injection on osteoporosis in Uygur elderly male patients in Xinjiang. Methods Forty-three Uygur elderly male patients with osteoporosis, who were hospitalized in our hospital from June 2010 to November 2011, were selected. All the patients were diagnosed with osteoporosis for the first time, and had not received any anti-osteoporosis treatment. Other bone metabolic disease or drug effects were also excluded. All the patients were randomly divided into treatment group (n=22, with an average age of 73.2 years old) and control group (n=21, with an average age of 73.8 years old). Patients in treatment group were given an intravenous drip of 5mg zoledronic acid for 30 minutes and an oral medication of caltrate D 600mg/d and alpha D3 0.25ug/d. Patients in control group were just given an oral medication of caltrate D 600mg/d and alpha D3 0.25ug/d. The whole treatment lasted for 1 year. The bone mineral density (BMD) of the lumbar vertebrae (L1-4), the femoral neck, and the Ward's triangle was detected using dual-energy X-ray absorptiometry (DEXA) before and after the treatment. Results Excluding 2 drop-out patients in treatment group, the increase of BMD in treatment group was significantly higher than that in control group (P<0.05). After the injection of zoledronic acid, 5 patients had fever, headache, and influenza-like symptoms. The symptoms of all the 5 patients relieved in 3 days after using NSAIDs. And no other adverse reactions were observed. Conclusion The injection of 5mg zoledronic acid can obviously improve BMD, inhibit bone loss, reduce fracture risks, and improve the patients’ compliance in Uygur elderly male patients with osteoporosis in Xinjiang. And the adverse reactions can be tolerated. So, 5mg zoledronic acid injection is a new efficient method for the treatment of osteoporosis in Uygur elderly male patients in Xinjiang. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|